Meilan Rutter is board-certified in pediatric endocrinology, and has been on the faculty of Cincinnati Children’s Hospital Medical Center and the University of Cincinnati since 2008. She completed her training in the United Kingdom, New Zealand and Cincinnati. She serves as the medical director of the Cincinnati Children’s Differences of Sex Development (DSD) Center and the assistant director of the pediatric endocrinology fellowship training program.
Dr. Rutter cares for children and adolescents with a wide spectrum of endocrine conditions, including growth, puberty, thyroid and adrenal disorders. She collaborates with interdisciplinary specialists to deliver the endocrine aspects of comprehensive and integrated care for patients with complex conditions. She leads the Cincinnati Children’s DSD Center, which provides interdisciplinary care for people born with conditions affecting reproductive development. The DSD Center is a member of the DSD-Translational Research Network, a national network that strives to optimize and standardize clinical practices and advance scientific knowledge in this field. Dr. Rutter also serves as the primary endocrine consultant for the Cincinnati Comprehensive Neuromuscular Center. In conjunction with the neuromuscular team, she has helped pioneer global awareness of the importance of endocrine issues in patients affected by Duchenne Muscular Dystrophy.
MB, BCh: University of Wales College of Medicine, Cardiff, United Kingdom.
FRACP: Royal Australasian College of Physicians, New Zealand.
Residency: University Hospital of Wales, Cardiff, United Kingdom; Auckland Children's Hospital, Auckland, and Dunedin Hospital, Dunedin, New Zealand; Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Fellowship: Pediatric Endocrinology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Certification: American Subspecialty Board of Pediatric Endocrinology, 2003, recertified 2013; American Board of Pediatrics, 2002; Fellow of the Royal Australasian College of Physicians (Pediatrics), 1995.
Pediatric endocrinology, including growth, puberty, thyroid and adrenal disorders; differences of sex development, or conditions affecting reproductive development; endocrine and bone health in neuromuscular conditions
Endocrinology, Fanconi Anemia, Leukemia, Neuromuscular Disorders, Diabetes, 22Q-VCFS, Differences of Sex Development, Sturge-Weber Syndrome
Differences of sex development; endocrine issues and bone health associated with Duchenne muscular dystrophy
Endocrinology
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Creation of an Electronic Resource Repository for Differences of Sex Development (DSD): Collaboration Between Advocates and Clinicians in the DSD-Translational Research Network. Sexual development : genetics, molecular biology, evolution, endocrinology, embryology, and pathology of sex determination and differentiation. 2023; 16:227-235.
Defining successful outcomes and preferences for clinical management in differences/disorders of sex development: Protocol overview and a qualitative phenomenological study of stakeholders' perspectives. Journal of Pediatric Urology. 2022; 18:36.e1-36.e17.
The effect of oral bisphosphonate therapy on vertebral morphometry and fractures in patients with Duchenne muscular dystrophy and glucocorticoid-induced osteoporosis. Muscle and Nerve. 2021; 64:710-716.
Emergency Planning as Part of Healthcare Transition Preparation for Patients with Duchenne Muscular Dystrophy. Journal of Pediatric Nursing. 2021; 61:298-304.
The Effect of Adiposity on Cardiovascular Function and Myocardial Fibrosis in Patients With Duchenne Muscular Dystrophy. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease. 2021; 10:e021037.
Age-related changes in appendicular lean mass in males with Duchenne muscular dystrophy: A retrospective review. Muscle and Nerve. 2021; 63:231-238.
Safety and efficacy of teriparatide treatment for severe osteoporosis in patients with Duchenne muscular dystrophy. Osteoporosis International. 2020; 31:2449-2459.
XY Gonadal Dysgenesis in a Phenotypic Female Identified by Direct-to-Consumer Genetic Testing. Pediatrics. 2020; 146.
Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy. Neuromuscular Disorders. 2020; 30:599-610.
Poorly differentiated thyroid carcinoma of childhood and adolescence: a distinct entity characterized by DICER1 mutations. Modern Pathology. 2020; 33:1264-1274.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey